Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.

Akouos is a new biotechnology company focused on restoring and preserving hearing. Launched in 2017 by Dr. Manny Simons, CEO, Akouos focuses on restoring and preserving hearing. In conjunction with the funding, Akouos entered into strategic license agreements with Lonza and Massachusetts Eye and Ear for exclusive rights to the Anc-AAV gene therapy platform for all hearing…

Tilos is developing new immuno-oncology therapies for cancer, fibrosis and autoimmunity based on interference with regulatory T cells and TGF release. This novel drug platform builds on the discovery that antibodies that block the release of TGF prevent immune suppression, thereby enabling the body to counteract malignant cells.

Keros lead program is focused on inhibition of ALK2, the genetic driver for the orphan disease fibrodysplasia ossificans progressive (FOP), which promotes the transformation of muscle into bone. ALK2 has been validated as a critical node through human genetics and in vivo data.

First-in-Class immuno-oncology agent complementary with existing therapies, and autoimmune drug for inclusion body myositis. Abcuro is pursuing a single Ab discovery campaign to yield two independent antibody therapeutic programs: 1. Anti-target depleter (autoimmunity) 2. Anti-target neutralizer (immuno-oncology)

ImmuneXcite is a product-focused biopharmaceutical company with a novel immuno-oncology technology platform which leverages both the innate and adaptive immune responses to selectively treat a wide range of tumor types.  

Lyndra’s sustained release formulation technology extends oral drug delivery beyond one week. The benefits of this unique technology include improved adherence, improved pharmacokinetic profiles, convenient patient experience (particularly for populations that lack easy access to care), decreased potential for antibiotic resistance, and reduced healthcare costs.

HealthCatalyst

Sebacia is developing a safe and durable treatment for acne that utilizes a laser-activated topical agent.

Spero Therapeutics is a product-focused biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The company’s pipeline of anti-infective agents is one of the most unique in the industry – focused exclusively on gram-negative bacterial infections.

Syntimmune is developing novel therapies for inflammatory diseases and life-threatening toxicities.

TargAnox, is an early-stage discovery company developing novel therapeutics for the treatment of diseases and conditions that result from oxidative stress-induced modification of proteins.